Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"The Next Best Way To Block Generics" May Be Novo's Patent Use Code Switch

Executive Summary

The generic industry has lined up against Novo Nordisk's maneuver to keep Caraco Pharmaceuticals from getting approval of a generic version of its diabetes drug Prandin

You may also be interested in...



Caraco Seeks Supreme Court Intervention In Its Prandin Patent Use Code Battle With Novo

Caraco asks the Supreme Court to decide whether it can file a counterclaim opposing Novo's revision of its patent use code for the diabetes drug.

Patent Use Codes May Still Block Generics As FDA Looks For Alternatives

FDA is assessing ways to alter how it handles patent use codes following charges they are being used to derail the approval of generics, but a straightforward solution has so far eluded the agency.

Patent Use Codes May Still Block Generics As FDA Looks For Alternatives

FDA is assessing ways to alter how it handles patent use codes following charges they are being used to derail the approval of generics, but a straightforward solution has so far eluded the agency.

Related Content

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel